1246 University Ave. W., #301
11 articles about Recombinetics
Recombinetics Inc. Announces Study to Improve Outcomes for Rare Disease Patients
Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a first-of-its-kind study to improve outcomes for patients diagnosed with a rare disease known as Tuberous Sclerosis Complex (TSC). Surrogen, a subsidiary of Recombinetics Inc., is focused on d
Recombinetics Inc. to Partner with American Preclinical Services to Improve Glioblastoma Outcomes
Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced that it has partnered with American Preclinical Services in a first of its kind study to improve Glioblastoma outcomes.
Recombinetics Inc. Merges with Makana Therapeutics to Accelerate Xenotransplantation
- Recombinetics Inc., a leading gene editing company with platform technology in therapeutics development, today announced that it has merged its efforts with Makana Therapeutics, a leader in the field of xenotransplantation.
Recombinetics Announces New Chief Executive Officer
Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today named Mark Platt the organization’s Chief Executive Officer.
Recombinetics Closes $34 Million in Series A Funding
Recombinetics, a pioneer in gene-editing solutions for human health and animal agriculture, today announced the completion of a $34 million Series A financing round.
Recombinetics Release: Company Expands Its Scientific Advisory Board
Recombinetics Closes $10 Million Stock Offering
Recombinetics Awarded Two NIH Grants To Develop Humanized Swine Models Of Alzheimer's Disease And Neurofibromatosis 2
Gene-Editing Startup Recombinetics Names Former General Mills Exec as CEO
Recombinetics Release: First Published Research Shows Success With Targeted Gene-Editing to Accelerate Genetic Improvement in Dairy Cattle
Cellectis BioResearch Grants Recombinetics an Exclusive License Agreement for the Use of Targeted Nucleases in Large Livestock